AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Money Concepts Capital Corp

Money Concepts Capital Corp trimmed its position in AstraZeneca PLC (NASDAQ:AZN) by 2.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 32,745 shares of the company’s stock after selling 861 shares during the quarter. Money Concepts Capital Corp’s holdings in AstraZeneca were worth $2,145,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. Stratos Wealth Advisors LLC raised its stake in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares in the last quarter. Crumly & Associates Inc. raised its position in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares in the last quarter. Diversify Wealth Management LLC lifted its holdings in AstraZeneca by 3.6% in the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after acquiring an additional 153 shares during the last quarter. Veery Capital LLC boosted its position in shares of AstraZeneca by 4.7% during the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after purchasing an additional 157 shares in the last quarter. Finally, Harbour Investments Inc. grew its stake in shares of AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after purchasing an additional 160 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Trading Up 2.9 %

AstraZeneca stock opened at $70.93 on Thursday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm has a market capitalization of $219.96 billion, a price-to-earnings ratio of 33.94, a P/E/G ratio of 1.18 and a beta of 0.46. The company has a 50 day moving average price of $67.20 and a 200 day moving average price of $73.72.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the firm earned $0.87 earnings per share. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. Research analysts forecast that AstraZeneca PLC will post 4.13 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.